# EU-1-11-729_public-assessment-report_20111208_20140402_onduarp-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH
22 September 2011
EMA/891763/2011
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Onduarp
thorised
International non-proprietary name: telmisartan / amlodipine
Procedure No. EMEA/H/C/002118
st no longer a
Assessment Report as agopted by the CHMP with all
information of a commercially confidential nature deleted
Medicinal pro
7 Westferry Circus . Canary Wharf . London E14 4HB . United Kingdom
Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455
E-mail info@ema.europa.eu Website www.ema.europa.eu
An agency of the European Union
European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged.
Table of contents
1. Background information on the procedure
4
1.1 Submission of the dossier
4
Information on Paediatric requirements
4
Information relating to orphan market exclusivity.
4
Scientific Advice
4
4
Licensing status
5
1.2 Steps taken for the assessment of the product.
2. Scientific discussion
6
2.1 Introduction
6
2.2
Quality aspects
6
2.3
Non-clinical aspects
6
2.4
Clinical aspects
8
2.5
Pharmacovigilance
8
2.6 User consultation
9
3. Benefit-Risk Balance
4. Recommendations
9
Outcome
10
10
Conditions or restrictions regarding supply and use
10
Conditions and requirements of the marketing authorisation
10
Medicinal product no xonger authorised.
Onduarp
Assessment report EMA/891763/2011
Page 2/10
